Australia markets open in 2 hours 34 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
18.45-0.10 (-0.54%)
At close: 04:00PM EST
18.45 0.00 (0.00%)
After hours: 04:34PM EST

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270

Full-time employees236

Key executives

NameTitlePayExercisedYear born
Dr. Joseph K. BelanoffCo-Founder, Pres, CEO & Director1.52MN/A1957
Dr. Hazel Hunt Ph.D.Chief Scientific Officer674.87k946kN/A
Mr. Sean MaduckChief Commercial Officer688.54kN/A1977
Mr. Gary Charles RobbChief Bus. Officer & Sec.795.62kN/A1963
Mr. Atabak MokariChief Financial OfficerN/AN/A1977
Mr. Joseph Douglas LyonChief Accounting OfficerN/AN/A1978
Dr. Christopher Shayne James M.D.Director of Investor RelationsN/AN/AN/A
Ms. Amy FloodChief HR & Communications OfficerN/AN/AN/A
Donald E. LaferleSr. VPN/AN/AN/A
Dr. William Guyer Pharm.D.Chief Devel. OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Corporate governance

Corcept Therapeutics Incorporated’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.